PE
NVAX icon

Point72 Europe’s Novavax NVAX Stock Holding History

Point72 Europe’s Portfolio NVAX Stock Details NVAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		$41.8K Buy
+4,825
New +$37.6K ﹤0.01% 390

Other funds holding NVAX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCM
Shah Capital Management Raleigh, North Carolina $521M AUM 46.95% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
S
Sanofi Paris, France $336M AUM 126.85% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Coatue Management
Coatue Management New York $29.1B AUM 96.54% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Point72 Europe's NVAX Position: Q3 2025 in Review

Point72 Europe opened a new position in Novavax (NVAX) in Q3 2025: 4,825 shares worth $41.8K. The stake represents ﹤0.01% of the portfolio and ranks #390 among its holdings.

249 funds tracked by Wall St. Rank hold NVAX as of Q3 2025.

  • Point72 Europe held 4,825 shares of Novavax worth $41.8K as of Q3 2025.
  • Novavax was a new Point72 Europe position in Q3 2025.
  • Novavax made up ﹤0.01% of Point72 Europe's portfolio in Q3 2025, its #390 holding.
  • 249 funds tracked by Wall St. Rank held Novavax as of Q3 2025.

Based on Point72 Europe's 13F filing for Q3 2025, filed 14 Nov 2025.